secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001104659-24-087013
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics Q2 2024: Cash $269.6M, initiates Phase 1 SLE trial, advances CNTY-101
--------------------------------------------------------------------------------

- Initiated Phase 1 CALiPSO-1 trial of CNTY-101 in Systemic Lupus Erythematosus, with protocol amended to include Lupus Nephritis cohort; expects initial data by year-end 2024.
- Presented interim ELiPSE-1 trial data at ASCO showing encouraging efficacy and tolerability in relapsed/refractory B-cell lymphomas; dose escalation completed, dose expansion expected in 2H 2024.
- Ended Q2 2024 with $269.6 million cash, equivalents, and investments; cash runway into 2026. GAAP operating expense guidance $150-$160 million.
- Completed $60 million private placement and acquired Clade Therapeutics in April 2024, enhancing Allo-Evasion platform and adding preclinical αβ iT programs.
- R&D expenses $27.2 million for Q2 2024 vs $22.7 million prior year; net loss $31.2 million vs $33.3 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924087013/0001104659-24-087013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924087013/tm2421030d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-087013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer